News | December 26, 2023
Astellas completes acquisition of Propella Therapeutics
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Ami Organics will also sign an MoU with Government of Gujarat for investment amounting up to Rs 300 crores for set up of dedicated manufacturing facility for electrolytes business
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Development services for gene and cell therapies is planned to begin first in 2025
Clariant Healthcare highlighted Vitipure Meglumine LEX and VitiPure Superior at the recently concluded CPhI India
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
Subscribe To Our Newsletter & Stay Updated
